ストックスクリーナーアプリを入手
198.50
2.63%
-5.37
アフターアワーズ：
198.03
-0.47
-0.24%
前日終値:
$203.87
開ける：
$193.72
24時間の取引高:
2.16M
Relative Volume:
1.46
時価総額：
$28.79B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
19.14
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
-9.11%
1か月 パフォーマンス:
+1.91%
6か月 パフォーマンス:
-22.06%
1年 パフォーマンス:
-21.97%
1日の値動き範囲:
$190.25
$200.55
1週間の範囲:
$190.25
$219.98
52週間の値動き範囲:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
198.50 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
407.12 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
153.83 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.58 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
69.00 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges - TradingView
Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges - PR Newswire
Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34 - Moomoo
Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270 - Moomoo
ResMed stock reflects steady demand for sleep apnea solutions - ad-hoc-news.de
Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 - marketscreener.com
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed Stock Sinks as Citi Sounds Supply Alarm - TipRanks
ResMed Inc. stock falls Wednesday, underperforms market - MSN
In an era of ‘baddies,’ companies are racing to keep up with the influencer economy - CNN
ResMed (RMD) Divestiture of MatrixCare presentation Summary - Quartr
ResMed Is Maintained at Hold by Jefferies - Moomoo
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - Yahoo Finance
Jefferies Adjusts Price Target on ResMed to $225 From $240 - marketscreener.com
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health - Yahoo Finance
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Ord Minnett - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie - The Globe and Mail
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact - simplywall.st
ResMed Analyst Backs Portfolio Reset - Benzinga
ResMed's Q4 2026 Earnings: What to Expect - Yahoo Finance
Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and ResMed - Yahoo Finance
What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares? - Kalkine
ResMed chairman & CEO Michael Farrell sells $1.09m in company stock - Investing.com
Form 4 ResMed Inc For: 9 July By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing - marketscreener.com
ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan - Stock Titan
ResMed Inc. highlights sleep and respiratory focus as investors track Nasdaq-listed shares - Ad-hoc-news.de
ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says - marketscreener.com
ResMed to sell MatrixCare business to Frazier Healthcare Partners - MSN
ResMed's billion-dollar blowup - intelligentinvestor.com.au
ResMed's $490M Sale Looks Strategically Sound -- Market Talk - Moomoo
Is ResMed Inc (RMD) a Bargain After 6.3% Drop? GF Value Says Und - GuruFocus
Resmed Agrees to Sell its Software Business to a Private Equity Firm - Medical Product Outsourcing
Why ResMed Is Dropping 5.7%: RBC Capital Maintains Outperform - AlphaStreet
ResMed (NYSE:RMD): Why The Market Is Watching? - Kalkine Media
Resmed to sell MatrixCare for $490M to private equity firm - RamaOnHealthcare
ResMed Inc. focuses on sleep and respiratory care. Long-term demand supports the business model. - AD HOC NEWS
ResMed stock held at Hold by Needham as MatrixCare sale announced - Investing.com Nigeria
ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says - marketscreener.com
RBC Capital Maintains ResMed(RMD.US) With Buy Rating, Cuts Target Price to $276 - Moomoo
Frazier Healthcare Partners Acquires MatrixCare - Hospice News
Resmed sharpens sleep care focus with $490m software business sale - Yahoo Finance
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $225 to $320 - Moomoo
ResMed Sells MatrixCare Software Business For $490m In Portfolio Overhaul - insights.citeline.com
Wells Fargo Adjusts Price Target on ResMed to $225 From $227 - marketscreener.com
RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating - marketscreener.com
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion - ChartMill
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
1.69%
1.12%
大文字化:
|
ボリューム (24 時間):